Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 17/20 | 0.51 |
| ▸ | ICAM1 | P05362 | 17/20 | 0.51 |
| ▸ | ITGAL | P20701 | 17/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19158403 | 0.91 | ITGB2 (0.54) | ITGB2ICAM1ITGALALDH1A1HPGD | |
| SCHEMBL23153603 | 0.90 | ITGB2 (0.65) | ITGB2ICAM1ITGAL | |
| SCHEMBL16270942 | 0.83 | ITGB2 (0.50) | ITGB2ICAM1ITGALRAB9ANPC1 | |
| SCHEMBL18868110 | 0.83 | ITGB2 (0.66) | ITGB2ICAM1ITGAL | |
| SCHEMBL12169799 | 0.83 | ITGB2 (0.66) | ITGB2ICAM1ITGAL | |
| SCHEMBL4756084 | 0.83 | ITGB2 (0.67) | ITGB2ICAM1ITGAL | |
| SCHEMBL17991464 | 0.82 | ITGB2 (0.63) | ITGB2ICAM1ITGAL | |
| SCHEMBL13894279 | 0.82 | ITGB2 (0.63) | ITGB2ICAM1ITGAL | |
| SCHEMBL17991445 | 0.82 | ITGB2 (0.63) | ITGB2ICAM1ITGAL | |
| SCHEMBL25912568 | 0.81 | ITGB2 (0.43) | ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3195861-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DRY EYE DISORDERS | SARcode Bioscience Inc. (US) | 2017-07-26 | — | — | EP | disclosed |